New York State Common Retirement Fund Purchases 1,945 Shares of Shockwave Medical, Inc. (NASDAQ:SWAV)

New York State Common Retirement Fund lifted its position in Shockwave Medical, Inc. (NASDAQ:SWAV) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 209,395 shares of the company’s stock after buying an additional 1,945 shares during the period. New York State Common Retirement Fund owned about 0.57% of Shockwave Medical worth $39,902,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Robbins Farley boosted its stake in shares of Shockwave Medical by 1.0% during the 4th quarter. Robbins Farley now owns 4,542 shares of the company’s stock worth $866,000 after buying an additional 45 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Shockwave Medical by 11.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 483 shares of the company’s stock valued at $96,000 after purchasing an additional 50 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. Treasurer of the State of North Carolina lifted its stake in Shockwave Medical by 0.4% in the 3rd quarter. Treasurer of the State of North Carolina now owns 16,390 shares of the company’s stock valued at $3,263,000 after purchasing an additional 60 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in Shockwave Medical by 23.1% in the 3rd quarter. First Horizon Advisors Inc. now owns 437 shares of the company’s stock valued at $87,000 after purchasing an additional 82 shares during the last quarter. 95.35% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Shockwave Medical

In related news, CEO Douglas Evan Godshall sold 10,000 shares of Shockwave Medical stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $231.56, for a total value of $2,315,600.00. Following the transaction, the chief executive officer now directly owns 162,762 shares of the company’s stock, valued at $37,689,168.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Shockwave Medical news, Director Laura Francis sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total value of $450,000.00. Following the sale, the director now owns 3,551 shares in the company, valued at $1,065,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas Evan Godshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $231.56, for a total transaction of $2,315,600.00. Following the completion of the sale, the chief executive officer now owns 162,762 shares in the company, valued at approximately $37,689,168.72. The disclosure for this sale can be found here. Insiders have sold 93,813 shares of company stock valued at $23,762,679 over the last three months. 3.40% of the stock is owned by insiders.

Shockwave Medical Stock Performance

Shares of NASDAQ:SWAV opened at $328.87 on Thursday. The company’s 50 day simple moving average is $291.68 and its 200 day simple moving average is $231.69. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of 84.98, a price-to-earnings-growth ratio of 2.44 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. Shockwave Medical, Inc. has a 1 year low of $157.00 and a 1 year high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last announced its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. The business had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same period last year, the firm posted $3.71 earnings per share. As a group, research analysts predict that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SWAV shares. Wells Fargo & Company raised their target price on shares of Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Morgan Stanley reissued an “equal weight” rating and issued a $335.00 price target (up from $285.00) on shares of Shockwave Medical in a report on Monday, April 8th. Needham & Company LLC reissued a “hold” rating on shares of Shockwave Medical in a report on Friday, April 5th. SVB Leerink reissued a “market perform” rating and issued a $335.00 price target (down from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th. Finally, Wolfe Research reissued a “peer perform” rating on shares of Shockwave Medical in a report on Friday, April 5th. Ten equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $309.11.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.